S-1: AIM ImmunoTech Launches $12M Rights Offering Amid NYSE Compliance Concerns

Sentiment:

Rights Offering Prospectus 11 December 2025 6:21 PM

AIM ImmunoTech Inc. is conducting a non-transferable subscription rights offering to raise up to $12 million by selling units consisting of Series G Convertible Preferred Stock and Warrants.

Delay expectedThe planned Phase 2 study of Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer was placed on hold and suspended in February 2025, pending additional data from the ongoing DURIPANC clinical trial.

Capital raiseThe company is conducting a non-transferable subscription rights offering to purchase up to 12,000 Units.Each Unit consists of one share of Series G Convertible Preferred Stock and Warrants to purchase common stock, at a subscription price of $1,000 per Unit.The offering aims to raise up to $12 million in gross proceeds, with estimated net proceeds of approximately $10.9 million after deducting fees and expenses.Proceeds will be used for general corporate purposes, repayment of existing debt obligations (two unsecured notes of approximately $3.3 million each), and approximately $2 million for Ampligen manufacturing for a potential Phase 3 trial.The offering is being conducted on a 'best-efforts basis' and there is no minimum amount of proceeds necessary to be received for the company to close the offering.The board of directors and executive team have indicated their intent to participate in the Rights Offering.

Worse than expectedThe company's stockholders' deficit was approximately negative $6.1 million as of September 30, 2025, which is below the NYSE American's minimum requirement of $6 million in stockholders' equity, indicating a precarious financial position.The capital raise is necessary to fund ongoing operations and expansion, and to repay existing debt obligations, highlighting an urgent need for external financing to maintain solvency and operations.The previous Phase 2 pancreatic cancer study was placed on hold and suspended in February 2025, indicating a setback in a key development area despite positive interim data from another trial.

Summary

AIM ImmunoTech Inc. is an immuno-pharma company focused on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders.
The company is launching a non-transferable subscription rights offering to raise up to $12 million in gross proceeds.
Each unit in the offering costs $1,000 and consists of one share of Series G Convertible Preferred Stock and warrants to purchase common stock.
The Series G Convertible Preferred Stock is convertible into common stock at a conversion price of an unspecified dollar amount per share.
Each warrant is exercisable for one share of common stock at an unspecified exercise price per share and expires five years from issuance.
The company's flagship product, Ampligen (rintatolimod), is approved for commercial sale in Argentina for severe Chronic Fatigue Syndrome (CFS) but not yet by the FDA in the U.S.
Clinical trials are ongoing for Ampligen in pancreatic cancer (DURIPANC Phase 1b/2) and it is being evaluated for other cancers, antiviral activities (including COVID-19, Long COVID, and avian influenza), and ME/CFS.
The company reported positive mid-year safety and efficacy data from the DURIPANC study, with no significant toxicity and 21% of 14 subjects showing progression-free survival (PFS) >6 months, and 64% overall survival (OS) >6 months.
Interim data from an ovarian cancer trial showed an Objective Response Rate (ORR) of 50% (5 complete responses, 7 partial responses) in 24 evaluable patients out of 27.
AIM ImmunoTech is not in compliance with NYSE American's stockholders' equity rule, with a stockholders' deficit of approximately negative $6.1 million as of September 30, 2025, below the required $6 million minimum.
Net proceeds from the offering, estimated at $10.9 million after fees and expenses, will be used for general corporate purposes, debt repayment, and manufacturing Ampligen for a potential Phase 3 pancreatic cancer trial.

Sentiment

Score: 3

Explanation: While there are positive early-stage clinical trial updates for Ampligen, the company faces significant financial distress, evidenced by its negative stockholders' equity and non-compliance with NYSE American listing requirements. The rights offering, while necessary for capital, will cause substantial dilution for existing shareholders and is being conducted on a best-efforts basis with no minimum, indicating high uncertainty. The lack of a public market for the preferred stock and uncertainty regarding warrant listing further increase investment risk. The overall financial instability and the urgent need for funding outweigh the early clinical positives, leading to a low sentiment score.

Positives

Positive mid-year safety and efficacy update for the DURIPANC Phase 1b/2 trial in late-stage pancreatic cancer, showing no significant toxicity, 21% progression-free survival (PFS) >6 months, and 64% overall survival (OS) >6 months in eligible subjects.
Positive interim data from an investigator-initiated Phase 2 trial for recurrent platinum-sensitive ovarian cancer, demonstrating a 50% Objective Response Rate (ORR) (5 complete responses, 7 partial responses) when Ampligen was combined with pembrolizumab and cisplatin.
A patent application in the immuno-oncology space was granted by the Netherlands on March 15, 2021.
Management and members of the board of directors have indicated their intent to participate in the Rights Offering, signaling confidence.
The company is pursuing a study for a potential avian influenza combination therapy of Ampligen and AstraZeneca's FluMist, building on previous research showing increased immune response.

Negatives

The company is not in compliance with NYSE American's stockholders' equity rule, reporting a deficit of approximately negative $6.1 million as of September 30, 2025, which is below the required $6 million minimum.
A previously planned Phase 2 pancreatic cancer study was placed on hold and suspended in February 2025, pending additional data from the ongoing DURIPANC clinical trial.
The Subscription Rights are non-transferable and will not be listed for trading on any exchange, limiting liquidity for rights holders.
There is no public trading market for the Series G Convertible Preferred Stock, and the company does not intend to apply for its listing.
There is no assurance that the Warrants will be listed for trading on the NYSE American, despite the company's expectation to do so.
Significant dilution is expected for stockholders and securities holders who do not fully exercise their Subscription Rights.
The Rights Offering is being conducted on a best-efforts basis with no minimum amount of proceeds required, meaning the company may not raise sufficient capital to meet its objectives.
The Subscription Price does not necessarily bear any relationship to established criteria for value, and the market price of common stock may decline during or after the offering.
The company has not declared or paid dividends since its inception and does not plan to in the foreseeable future.
The auditor's report contains an explanatory paragraph regarding the company's ability to continue as a going concern, highlighting financial uncertainty.

Risks

Management will have broad discretion over the use of net proceeds from the Rights Offering, and these proceeds may not be invested successfully.
Existing stockholders who do not fully exercise their Subscription Rights will experience dilution of their proportional ownership interest.
Purchasers of Units in the Rights Offering may suffer immediate and substantial dilution in the net tangible book value of common stock.
The Rights Offering is not subject to a minimum offering amount, potentially leading to insufficient capital to meet company objectives.
The Rights Offering may cause the trading price of the company's common stock to decrease.
Holders of Preferred Stock and Warrants will have no rights as common stockholders until conversion or exercise.
The company may terminate the Rights Offering for any reason, with subscription monies returned without interest or deduction.
The Subscription Price is not an indication of the fair value of the company or its common stock.
Failure to act on a timely basis and follow subscription instructions may result in the rejection of Subscription Rights.
Subscribed Units may be reduced due to proration if the offering is oversubscribed.
Payment by personal check may not clear in sufficient time, leading to the inability to purchase shares.
The receipt of Subscription Rights may be treated as a taxable distribution for U.S. federal income tax purposes.
Proposed legislation in the U.S. Congress, including changes in U.S. tax law, may adversely impact the company and the value of its securities.
Exercising Subscription Rights limits the ability to engage in certain hedging transactions.
The Subscription Rights are non-transferable, and there is no market for them.
There is no public market for the Preferred Stock, and no assurance of a market developing for the Warrants.
The market price of common stock may never exceed the exercise price of the Warrants prior to their expiration.
Warrants, as executory contracts, may have no value in a bankruptcy or reorganization proceeding.
The company may amend or modify the terms of the Rights Offering at any time prior to its expiration.
The company is not currently in compliance with NYSE American continued listing requirements, risking delisting if compliance is not regained by June 11, 2026.
General business risks related to drug development, intellectual property, and regulatory matters are incorporated by reference from previous filings.

Future Outlook

The company intends to use the net proceeds from the Rights Offering for general corporate purposes, including research and development expenses, capital expenditures, working capital, general and administrative expenses, and general accounts payable. A portion of the proceeds will be allocated to repay existing debt obligations. Approximately $2 million is earmarked for manufacturing additional Ampligen to support a potential Phase 3 trial in advanced pancreatic cancer. The company also plans to pursue a study for a potential avian influenza combination therapy and is seeking collaborative grants to fund it. Pending use, funds will be invested in short-term, investment-grade, interest-bearing securities.

Management Comments

"We are prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer having priority over other experimentation."
"We intend that priority clinical work be conducted in trials authorized by the FDA or European Medicines Agency (EMA), which trials support a potential future NDA."
"We believe that this pre-clinical and clinical work to date — combined with the ever-growing threat of Avian influenza — strongly supports our decision to move forward with this second Ampligen and FluMist study in humans."
"The results support our belief in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of fatigue, and that this would be the likely subject population for any follow-up clinical trial."
"Our board of directors is making no recommendation regarding your exercise of the Subscription Rights."
"We intend to take all reasonable measures available to regain compliance under the NYSE American’s listing rules and remain listed on the NYSE American."

Industry Context

AIM ImmunoTech operates in the highly competitive immuno-pharma sector, focusing on challenging therapeutic areas such as oncology (pancreatic and ovarian cancers), viral diseases (including emerging threats like avian influenza and persistent conditions like Long COVID), and chronic immune disorders (ME/CFS). The company's strategy to combine Ampligen with checkpoint inhibitors aligns with a significant trend in immuno-oncology to enhance anti-tumor responses. Its pursuit of antiviral applications, particularly for avian influenza, positions it within the broader public health and pandemic preparedness landscape, often involving government and industry collaborations to de-risk and accelerate development.

Comparison to Industry Standards

The Netherlands study indicated Ampligen extended survival in pancreatic cancer patients 'well beyond the Standard of Care (SOC)' when compared to 'well-matched historical controls,' suggesting a potentially superior outcome, though specific comparative drug data is not provided.
The 50% Objective Response Rate (ORR) in the ovarian cancer trial combining Ampligen with pembrolizumab and cisplatin is a strong result for recurrent platinum-sensitive ovarian cancer, a difficult-to-treat indication. Pembrolizumab (Keytruda) is a leading checkpoint inhibitor, and its combination with Ampligen suggests a synergistic effect, which is a key area of research in immuno-oncology.
The company's stockholders' deficit of approximately negative $6.1 million as of September 30, 2025, falls significantly below the NYSE American's minimum listing requirement of $6 million in stockholders' equity, indicating a financial position that is substantially weaker than typical publicly traded companies on major exchanges.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Stockholder Rights Plan	The company has a Rights Agreement (poison pill) in place, which could deter hostile takeovers.	November 19, 2002 (original declaration), subsequently amended and restated.	Enhances the board's ability to resist unsolicited acquisition proposals, potentially protecting continuity of management but also limiting stockholder ability to effect change.
Board Authority to Issue Preferred Stock	The board of directors is authorized to issue up to 5,000,000 shares of preferred stock in one or more series without stockholder approval, with rights, preferences, privileges, and restrictions fixed by the board.	As per Certificate of Incorporation	Provides flexibility for future financings and acquisitions but could dilute the voting power of common stock, impair liquidation rights, or delay/prevent a change of control.
Bylaw Provisions for Director Vacancies	Any vacancy occurring in the board of directors may be filled by the affirmative vote of a majority of the remaining directors.	As per Bylaws	Enhances the board's control over its composition, potentially limiting stockholder influence.
No Preemptive Rights for Stockholders	Stockholders do not have preemptive rights to purchase shares in any future issuance of common stock.	As per Bylaws	Allows the company to issue new shares without offering them proportionally to existing shareholders, potentially leading to dilution.
Advance Notice Provisions for Stockholder Proposals and Nominations	Stockholders must give timely written notice (no less than 60 days nor more than 90 days prior to the prior meeting's date or ten days following the day on which the meeting is first made) for board nominations or other business.	As per Restated Bylaws	Makes it more difficult for stockholders to propose business or nominate directors without significant advance planning, potentially discouraging proxy contests.
Special Meetings of Stockholders	Special meetings of the stockholders may be called only by the board of directors pursuant to a resolution adopted by a majority of the total number of directors.	As per Bylaws	Limits stockholders' ability to call special meetings to address urgent matters or challenge management.
No Stockholder Action by Written Consent	The Certificate of Incorporation does not permit stockholders to act by written consent; any action must be effected at a duly called annual or special meeting.	As per Certificate of Incorporation	Requires formal meetings for stockholder actions, potentially slowing down decision-making or making it harder for activist investors to effect change.
Super-Majority Stockholder Vote for Certain Actions	Requires the affirmative vote of at least 80% of outstanding voting stock to amend or repeal certain anti-takeover provisions or reduce the number of authorized shares of common or preferred stock. An 80% vote is also required for any amendment to, or repeal of, the Bylaws by stockholders.	As per Certificate of Incorporation	Makes it significantly harder for stockholders to change fundamental corporate governance provisions or challenge board decisions related to capital structure.
Indemnification of Directors and Officers	The company indemnifies directors, officers, employees, and agents to the extent permitted by Delaware law, including for expenses, judgments, fines, and settlements. Personal liability of directors for breach of fiduciary duty is eliminated or limited, except for certain breaches.	As per Certificate of Incorporation and Delaware law	Protects management and directors from certain liabilities, potentially encouraging risk-taking but also making it harder to hold them accountable for certain actions. The SEC views indemnification for Securities Act liability as against public policy.

Related Party Transactions

Members of the board of directors and executive team have indicated their intent to participate in the Rights Offering.

Stakeholder Impact

Shareholders: Non-participating shareholders will experience significant dilution. Participating shareholders have the opportunity to maintain or increase their stake, but with high investment risk due to the company's financial condition and the nature of the offering.
Creditors: A portion of the proceeds from the Rights Offering will be used to repay existing debt obligations, which is positive for creditors.
Employees and Management: The capital raise provides necessary funding for ongoing operations, which supports employment. Management and board participation in the offering aligns their interests with the company's need for capital.
Patients and Research Community: Funding supports ongoing clinical trials and research and development for Ampligen across various diseases, potentially leading to new therapeutic options.
Regulatory Bodies (NYSE American): The company's non-compliance with listing requirements puts its NYSE American listing at risk, which could impact its ability to raise future capital and its public profile.

Next Steps

Complete the Rights Offering to raise capital for general corporate purposes, debt repayment, and Ampligen manufacturing.
Redesign or amend the suspended Phase 2 pancreatic cancer study, pending additional data from the ongoing DURIPANC clinical trial.
Continue enrollment and dosing in Phase 2 of the DURIPANC study for late-stage pancreatic cancer.
Pursue a study of a potential avian influenza combination therapy of Ampligen and AstraZeneca's FluMist.
Seek collaborative grants from government and industry to defray the cost of the avian influenza study.
Take all reasonable measures to regain compliance with NYSE American's listing rules by June 11, 2026.
Invest any unutilized net proceeds in short-term, investment-grade, interest-bearing securities.

Key Dates

Date	Description
November 19, 2002	Original declaration date of the dividend distribution of one Right for each outstanding share of common stock pursuant to the company's rights agreement.
February 2025	Business decision made to place screening/enrollment on hold and suspend the planned Phase 2 study for locally advanced/metastatic pancreatic cancer. Also, the company announced its intention to pursue a study of a potential avian influenza combination therapy.
January 2025	Final Clinical Study results from the AMP-518 Phase 2 study for post-COVID conditions were posted to ClinicalTrials.gov.
July 2025	Positive mid-year safety and efficacy update announced for the DURIPANC Phase 1b/2 clinical trial. The company also issued Class E, Class F, and pre-funded warrants.
September 30, 2025	Company's stockholders' deficit was approximately negative $6.1 million. Net tangible book value was approximately negative $8,117,686, or negative $2.94 per share. 4 patients were enrolled in the open-label expanded access treatment protocol for ME/CFS and Post-COVID Conditions.
November 2025	Publication of an abstract presented at SITC on the completed ovarian cancer trial was announced.
December 1, 2025	Last reported sale price of the company's common stock on the NYSE American was $1.55 per share.
December 11, 2025	Filing date of the S-1 Registration Statement.
June 11, 2026	Deadline for the company to regain compliance with NYSE American's stockholders' equity listing requirements.
TBD, 2025	Record date for the Rights Offering (5:00 p.m., Eastern Time).
TBD, 2026	Expiration date for the Subscription Rights (5:00 p.m., Eastern Time), unless extended or terminated.

Recommendation

sell

Despite some promising early-stage clinical data for Ampligen in pancreatic and ovarian cancers, the company faces severe financial distress, evidenced by its negative stockholders' equity and non-compliance with NYSE American listing requirements. The rights offering, while a necessary capital raise, will cause substantial dilution for existing shareholders and is being conducted on a best-efforts basis with no minimum, indicating high uncertainty regarding the amount of capital to be raised. The lack of a public market for the preferred stock and uncertainty regarding warrant listing further increase investment risk. The overall financial instability, the urgent need for capital, and the risk of delisting significantly outweigh the early clinical positives, leading to a 'sell' recommendation for risk-averse investors.

Keywords

AIM ImmunoTech, Rights Offering, Capital Raise, Series G Convertible Preferred Stock, Warrants, Ampligen, Pancreatic Cancer, Immuno-Oncology, Viral Diseases, ME/CFS, Post-COVID Condition, Avian Influenza, Drug Development, Biotechnology, Pharmaceuticals, NYSE American, Dilution, Clinical Trials, Corporate Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.